Status:
COMPLETED
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
Lead Sponsor:
Hospital Son Llatzer
Collaborating Sponsors:
Fundació d'investigació Sanitària de les Illes Balears
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The coronavirus disease 2019 (COVID-19) was classified as a pandemic by the World Health Organization (WHO) in March 2020. The SARS-COV-2 virus is easily transmissible and there is currently no approv...
Eligibility Criteria
Inclusion
- Ability to understand the HIP and sign the study IC
- male or female =/\> 18 years
- Patient hospitalized with a COVID-19 diagnosis by PCR on nasopharyngeal swabs or any other biological sample.
- Presence of respiratory symptoms and / or fever associated with COVID-19, with clinical evolution time for COVID-19 equal to or less than 7 days.
- Presence of pneumonia on chest X-ray and / or SatO2 \<94% aa.
- Sequential Organ Failure Assessment (SOFA) score ≤ 6.
- Accept the condition of complying with the procedures established in the protocol.
Exclusion
- Patients with a previous history of allergic transfusion reaction.
- Lactating or pregnant women and a positive pregnancy test.
- Patients who have been treated with plasma in the 21 days prior to the screening / baseline visit.
- Patients who are at the time of study, participating in another clinical trial.
- Patients who haven't completed all study procedures.
Key Trial Info
Start Date :
July 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04803370
Start Date
July 8 2020
End Date
September 1 2021
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Son Llatzer
Palma de Mallorca, Islas de Balears, Spain